In the subgroup of NSCLC patients, the treatment regime revealed as well that chemotherapeutic agents were applied to the majority of patients (95.5) followed by PD-1 inhibitors (72.4%), radiation (54.8%), PD-L1 inhibitors (27.9%), and surgery (20.8%), see Table 3. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.